(CercleFinance.com) – Roche announces a new partnership with Alnylam to develop and commercialize zilebesiran, an investigational drug currently in phase 2 for the treatment of hypertension, a disease that affects more than 1.2 billion adults worldwide.
Based on positive Phase 1 data, zilebesiran may be the best treatment for this disease, and has also demonstrated an acceptable safety profile supporting continued clinical development.
Under the agreement, the two groups will jointly market zilebesiran in the United States and share costs and benefits equally. Outside the United States, Roche obtains exclusive marketing rights.
Alnylam will receive an upfront payment of $310 million and will be eligible for development, regulatory and commercial milestones, as well as an equal share of US profits and losses and non-US royalties.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
